Drugs / SAHA
last change Sep 2018 re-read 2 minutes ago

SAHA

Developed for
plasma cell myeloma
Investigated by
M.D. Anderson Cancer Center

Trials 1 · a red edge is where a trial was stopped

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02114502 Sep 2014 → Sep 2018 plasma cell myeloma M.D. Anderson Cancer Center Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SAHA ClinicalTrials.gov intervention name — accepted as the source's own label NCT02114502
Route Oral “1,000 mg by mouth” NCT02114502